Press Archive - Arriello

Medical cannabis in Europe: a compelling opportunity

Medical cannabis in Europe is not covered by a harmonised regulatory framework. However, Arriello director of drug safety, Peter Kohut, argues that this should not deter pharma companies from pursuing this increasingly attractive opportunity.

The Biosimilars Opportunity – Driving Access to Treatment in Europe

Gabriela Marton, Regulatory Affairs Director and Quality Director at Arriello, highlights EU regulatory challenges and calls for policy changes and education to maximize the opportunity for biosimilars to enhance patient outcomes.

Navigating the European Market for Medical Cannabis

There is considerable variation in the regulatory approach to medical cannabis between European countries. Yet, despite the complexity, there are clear routes to market, reports Peter Kohut.

Why aren’t more companies automating PV data capture?

Why are Safety & Pharmacovigilance departments lagging in their application of smart technology, when the pressures on pharmaceutical organisations to capture, sift and process real-world adverse event data are vast, asks John Price, a life sciences regulatory and safety consultant and advisor to Arriello.

Maintaining Control: The importance of project management.

In process outsourcing, it's easy to neglect the role of formal project management to keep delivery on track; unless it's clinical research, biotech or pharma organisations commonly neglect this when transferring a service externally.

Running a tight ship: The importance of project management.

The importance of not leaving outsourcing outcomes to chance... When biotech and pharma organizations outsource activities it's too easy to neglect the importance of tight project management and stakeholder coordination, explains Arriello's COO Anna Lukyanova.